Suppr超能文献

刺激状态下壁细胞中的质子泵激活受胃酸分泌能力调节:一项人体研究。

Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.

作者信息

Metz David C, Ferron Geraldine M, Paul Jeffrey, Turner Mary Beth, Soffer Elaine, Pisegna Joseph R, Bochenek Wieslaw J

机构信息

University of Pennsylvania Health System, Philadelphia, USA.

出版信息

J Clin Pharmacol. 2002 May;42(5):512-9. doi: 10.1177/00912700222011562.

Abstract

Under normal physiological conditions, gastric acid production is controlled by a negative feedback mechanism. Proton pump inhibitors, such as pantoprazole, inhibit gastric acid secretion by irreversibly binding and inactivating luminally active hydrogen potassium ATPase. Recovery of acid production after treatment with a proton pump inhibitor is driven by new pump synthesis, activation of existing cytoplasmic pumps, or reversal of proton pump inhibition. The authors measured the time course of the inhibition and recovery of acid secretion in healthy volunteers following intravenous administration of pantoprazole to determine the rate of proton pump activation under maximally stimulated conditions. Gastric acid production was measured in 27 Helicobacter pylori negative healthy volunteers (mean age = 31 +/- 7 years; 17 men, 10 women) who received single doses of intravenous pantoprazole (20, 40, 80, or 120 mg) in the presence of a continuous intravenous infusion of 1 ug/kg/h of pentagastrin. From the time profile of acid secretion, the authors described the rate of change of acid output using an irreversible pharmacodynamic response model represented by the equation dR/dt = -k x R x Cpanto + Ln2/PPR x (Ro-R) and correlated the parameter values with demographic factors and gastric acid measurements. Mean stimulated acid output secretion was 21.6 +/- 18.4 mEq/h (range: 1.6-90.5) prior to the administration of pantoprazole and remained steady for 25 hours after placebo administration. Intravenous pantoprazole inhibited acid output in a dose-response fashion, with maximal inhibition (99.9%) occurring after an 80 mg dose. Mean proton pump recovery time was 37.1 +/- 21.0 hours (range: 6.7-75), and recovery was independent of the dose of pantoprazole. There was no association noted between proton pump recovery time and gender, age, race, body weight, or pantoprazole dose. However, there was an inverse correlation between acid output during baseline stimulation and recovery of acid secretion. Mean proton pump recovery time in stimulated normal human volunteers was 37.1 +/- 21.0 hours, with a range of 6.7 to 75 hours. The authors hypothesize that there may be a normal homeostatic mechanism that maintains acid secretory capability within a normal range by altering the rate of proton pump activation dependent on the individual's parietal cell mass. Abnormalities of this process may be responsible for the development of acid peptic disease in susceptible individuals.

摘要

在正常生理条件下,胃酸分泌受负反馈机制控制。质子泵抑制剂,如泮托拉唑,通过不可逆地结合并使腔内活性氢钾ATP酶失活来抑制胃酸分泌。用质子泵抑制剂治疗后胃酸分泌的恢复是由新泵的合成、现有细胞质泵的激活或质子泵抑制的逆转驱动的。作者测量了健康志愿者静脉注射泮托拉唑后胃酸分泌抑制和恢复的时间过程,以确定在最大刺激条件下质子泵激活的速率。在27名幽门螺杆菌阴性的健康志愿者(平均年龄 = 31 ± 7岁;17名男性,10名女性)中测量胃酸分泌,这些志愿者在持续静脉输注1 μg/kg/h的五肽胃泌素的情况下接受单剂量静脉注射泮托拉唑(20、40、80或120 mg)。根据胃酸分泌的时间曲线,作者使用由方程dR/dt = -k x R x Cpanto + Ln2/PPR x (Ro - R)表示的不可逆药效学反应模型描述了酸输出的变化率,并将参数值与人口统计学因素和胃酸测量值相关联。在给予泮托拉唑之前,平均刺激胃酸分泌量为21.6 ± 18.4 mEq/h(范围:1.6 - 90.5),给予安慰剂后25小时保持稳定。静脉注射泮托拉唑以剂量反应方式抑制酸输出,80 mg剂量后出现最大抑制(99.9%)。平均质子泵恢复时间为37.1 ± 21.0小时(范围:6.7 - 75),恢复与泮托拉唑剂量无关。质子泵恢复时间与性别、年龄、种族、体重或泮托拉唑剂量之间未发现关联。然而,基线刺激时的酸输出与胃酸分泌的恢复之间存在负相关。刺激的正常人类志愿者中质子泵的平均恢复时间为37.1 ± 21.0小时,范围为6.7至75小时。作者推测,可能存在一种正常的稳态机制,通过根据个体壁细胞量改变质子泵激活速率,将胃酸分泌能力维持在正常范围内。这一过程的异常可能是易感个体发生酸相关性疾病的原因。

相似文献

3
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Am J Gastroenterol. 1999 Oct;94(10):2874-80. doi: 10.1111/j.1572-0241.1999.01430.x.
4
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
J Clin Pharmacol. 2001 Feb;41(2):149-56. doi: 10.1177/00912700122009953.
6
Continuing development of acid pump inhibitors: site of action of pantoprazole.
Aliment Pharmacol Ther. 1994;8 Suppl 1:11-23. doi: 10.1111/j.1365-2036.1994.tb00211.x.

引用本文的文献

4
Gastric Hypersecretory States: Investigation and Management.
Curr Treat Options Gastroenterol. 2015 Dec;13(4):386-97. doi: 10.1007/s11938-015-0065-8.
6
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Clin Exp Gastroenterol. 2009;2:117-28. doi: 10.2147/ceg.s5765. Epub 2009 Nov 17.

本文引用的文献

2
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
J Clin Pharmacol. 2001 Feb;41(2):149-56. doi: 10.1177/00912700122009953.
3
Effect of age and Helicobacter pylori infection on gastric acid secretion.
J Gastroenterol Hepatol. 2000 Mar;15(3):277-83. doi: 10.1046/j.1440-1746.2000.02131.x.
4
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Gastroenterology. 2000 Apr;118(4):696-704. doi: 10.1016/s0016-5085(00)70139-9.
5
PACAP type I receptor activation regulates ECL cells and gastric acid secretion.
J Clin Invest. 1999 Nov;104(10):1383-91. doi: 10.1172/JCI7537.
6
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Am J Gastroenterol. 1999 Oct;94(10):2874-80. doi: 10.1111/j.1572-0241.1999.01430.x.
7
8
Pharmacokinetics and absolute bioavailability of lansoprazole.
Eur J Clin Pharmacol. 1996;50(4):293-7. doi: 10.1007/s002280050111.
9
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Gastroenterology. 1993 May;104(5):1356-70. doi: 10.1016/0016-5085(93)90344-c.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验